Abstract
Cellular transformation does not necessarily require the expression of proteins with neoantigenic properties, and for this reason, immunosurveillance does not register all tumor cells. They frequently express potentially immunogenic components, but are able to escape elimination by immune mechanisms. One explanation for this escape is poor antigen presentation by the tumor cells, resulting in little or no measurable antitumor immunity in immunocompetent hosts. T cells remain naive or even become anergic to the tumor cells. Reasons for the deficient antigen presentation by the tumor cells include the reduced or absent expression of major histocompatibility complex (MHC) molecules and the absence of tumor antigens in the groove of class I or class II MHC molecules as a consequence of defective protein processing. Other reasons are the absence or inadequate levels of expression of adhesion molecules, the absence or inadequate levels of costimulatory molecules or the expression of lymphocyte suppressive cytokines like transforming growth factor (TGF-β) or interleukin 10 (IL-10) by tumor cells (1-5).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Refisto, N. P., Kawakami, Y., Marincola, F., Shamamiau, P., Taggarse, A., Esquivel, F., et al. (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogene therapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14, 182–190.
Allison, J. P., Hurwitz, A. A., and Leach D. R. (1995) Manipulation of costimulatory signals to enhance antitumor T cell responses. Curr. Opinion Immunol. 7, 682–686.
Guinan, E. V., Gribben, J. G., Boussiotis, V. A., Freeman G. J., and Nadler, L. M. (1994) Pivotal role of B 7: CD 28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261–3282.
Marrack, P. and Kappler, J. (1994) Subversion of the immune system by pathogens. Cell 76, 323–332.
Moore, K. W., O’Garra, A., and de Waal Malefyt, R. (1993) Interleukin 10. Annu Rev. Immunol. 11, 165–171.
Grimm, E. A., Muzumber, A., Zhang, H. Z., and Rosenberg, S. A. (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human periferal blood lymphocytes. J. Exp. Med. 155, 1823–1841.
Parmiani, G. (1990) An explanation of the variable clinical response to the interleukine 2 and LAK cells. Immunol. Today 11, 113–115.
Rosenberg, S. A., Spiess, P. J., and Lafrenière, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233, 1318–1321.
Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topolian, S. L., Schwarzentruber, D. J., Weber, J. S., et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159–1166.
Rosenberg, S. A. (1992). The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180–199.
Fisher, B., Packard, B., and Read, E. (1989) Tumor localization of adoptively transfered indium 111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250–261.
Waldmann, T. A. (1991) Monoclonal antibodies in diagnosis and therapy. Science 253, 1657–1662.
Brocker, T., Peter, A., Tannecker, A., and Karjalainen, K. (1993) New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23, 1435–1439.
Eshar, Z., Waks, T., Gross, G., and Schindler, D. J. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc. Natl. Acad. Sci. USA 90, 720–724.
Moritz, D., Wels, W., Mattern, F., and Groner, B. (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for erbB2 expressing tumor cells. Proc. Natl. Acad. Sci. USA 91, 4318–4322.
Hwu, P., Schafer, G. E., Theisman, J., Schindler, D. G., Gross, G., Cowherd, R., et al. (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with chimeric gene composed of antibody variable region and the Fc receptor γ chain. J. Exp. Med. 178, 361–366.
Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K., and Bolhuis, S. (1996) Single chain Ig/gammma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells and recycle lytic capacity. J. Immunol. 157, 836–843.
Morgenstern, J. P. and Land, H. (1990) A series of mammalianexpression vectors and characterization of a reporter gene in stably and transiently transfected cells. Nucleic Acid Res. 18, 3587–3596.
Moritz, D., et al. (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2expressing tumor cells. Proc. Natl. Acad. Sci. USA 91, 4318–322.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Maurer-Gebhard, M., Azémar, M., Altenschmidt, U., Humar, M., Groner, B. (2000). Direction of the Recognition Specificity of Cytotoxic T Cells Toward Tumor Cells by Transduced, Chimeric T-Cell Receptor Genes. In: Bartlett, J.M.S. (eds) Ovarian Cancer. Methods in Molecular Medicine™, vol 39. Humana Press. https://doi.org/10.1385/1-59259-071-3:749
Download citation
DOI: https://doi.org/10.1385/1-59259-071-3:749
Publisher Name: Humana Press
Print ISBN: 978-0-89603-583-6
Online ISBN: 978-1-59259-071-1
eBook Packages: Springer Protocols